1. ALLA AKTIER
  2. NYHETER
  3. ICONOVO

Iconovo

Nyheter Iconovo Nyheter alla bolag

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies

Iconovo AB (publ), which develops complete inhalation products for a global market, today announces that it has entered into a feasibility agreement with Affilogic, a French biotech company, regarding the implementation of a feasibility study of inhalable affinity proteins Nanofitins® in Iconovo's ICOone. The project aims to develop a new treatment for lung diseases.

Our new customer project adds additional value to Iconovo, with significant knowledge about the development of biological drugs, a growing market where we see great potential for our unique inhalers. We look forward to a close collaboration with Affilogic and have good hopes of being able to expand our collaboration in the future, says Johan Wäborg, CEO of Iconovo.

After the completion of the feasibility study, the biotech company has the opportunity to enter into a license agreement with Iconovo for the use of the treatment in one of the company's inhaler platforms with certain rights to exclusivity. Possible future license agreements may generate additional revenue through development work, milestone and royalty payments, or sales of inhalers.

Contacts

Johan Wäborg, CEO
+46 707 78 51 71
johan.waborg@iconovo.se

About Iconovo

Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.

Attachments

Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies

Datum 2023-06-19, kl 08:15
Källa MFN
Bifogade filer
Iconovo initiates feasibility study with Affilogic for development of inhalable Nanofitin®-based biotherapies
Vill du synas här? Kontakta hej@allaaktier.se. Vår sajt har 100 000 sidvisningar och 10 000 unika besökare per månad. Vår discord har över 5000 medlemmar. Detta är aktiva sparare med ett stort aktieintresse. Behöver du nå ut till denna målgrupp så hör av dig!